- Conditions
- Sleep Apnea, Obstructive, Obesity, Overweight
- Interventions
- Eloralintide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 23
- States / cities
- Cullman, Alabama • Long Beach, California • Los Alamitos, California + 19 more
Condition Directory
Obesity clinical trials
Directory of U.S. ClinicalTrials.gov public records for Obesity. Browse Obesity recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 30, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
6025
Shown on this page
12
Current sort
Recently updated
Condition scope
Obesity
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Obesity studies are organized in the registry
Obesity research spreads across several neighboring registry terms — “overweight,” “weight loss,” and “metabolic syndrome” all label closely related studies — so checking more than one term gives a fuller picture. The portfolio includes many behavioral and lifestyle studies alongside drug trials, which makes the study-type filter (interventional vs. observational) more informative than usual.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 193–204 of 6,025 matching trials for Obesity.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Overweight, Obesity
- Interventions
- Macupatide, Eloralintide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 40
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more
- Conditions
- Obesity, Overweight
- Interventions
- Eloralintide, Combined oral contraceptive
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Dallas, Texas
- Conditions
- Obesity, Overweight
- Interventions
- LY4329090, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Dallas, Texas
- Conditions
- Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Interventions
- CARE, TARE, Home-Based Stretching
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
- Interventions
- Orforglipron, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,001 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 80
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Pelham, Alabama + 73 more
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
- Interventions
- Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 204
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
- Conditions
- Osteoarthritis, Overweight or Obesity
- Interventions
- Eloralintide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 39
- States / cities
- Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 34 more
- Conditions
- Body Mass Index Greater Than or Equal to 30, Malignant Breast Neoplasm, Mammoplasty Patient, Obesity
- Interventions
- Negative Pressure Wound Therapy, Wound Care Management
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Obesity
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 24
- States / cities
- Escondido, California • New Haven, Connecticut • Columbus, Georgia + 19 more
- Conditions
- Crohn's Disease, Obesity or Overweight
- Interventions
- Mirikizumab, Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 35
- States / cities
- Dothan, Alabama • Anaheim, California • Beverly Hills, California + 29 more
- Conditions
- Overweight and Obesity
- Interventions
- Active Implicit Priming, Control Implicit Priming, Food Exposure Task
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
About this Obesity clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Obesity as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Obesity.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Obesity.